Credit Suisse Group Reiterates “$80.00” Price Target for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ:GILD) has been given a $80.00 target price by investment analysts at Credit Suisse Group in a research note issued on Wednesday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price suggests a potential upside of 2.28% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Citigroup reaffirmed a “buy” rating and issued a $105.00 price target (up from $103.00) on shares of Gilead Sciences in a research note on Thursday. TheStreet cut Gilead Sciences from a “b-” rating to a “c” rating in a research note on Tuesday. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Finally, Leerink Swann reduced their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $86.89.

Shares of Gilead Sciences (GILD) traded down $4.54 during trading on Wednesday, hitting $78.22. The company had a trading volume of 13,853,275 shares, compared to its average volume of 9,270,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market capitalization of $102,150.00, a P/E ratio of 22.48, a PEG ratio of -1.77 and a beta of 1.22. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 48.88% and a net margin of 17.73%. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.70 earnings per share. equities analysts predict that Gilead Sciences will post 6.47 EPS for the current year.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 578,333 shares of company stock worth $44,100,508 over the last ninety days. 1.30% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Bank of New York Mellon Corp lifted its holdings in Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after acquiring an additional 310,607 shares during the period. FMR LLC lifted its holdings in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Finally, Parnassus Investments CA lifted its holdings in Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after acquiring an additional 464,609 shares during the period. 75.84% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/08/credit-suisse-group-reiterates-80-00-price-target-for-gilead-sciences-gild-2.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply